-- Shenzhen Hepalink Pharmaceutical (HKG:9989, SHE:002399) posted net profit attributable to shareholders of 187.6 million yuan for the first quarter, up 20% from 156.6 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.
Hong Kong-listed shares of the pharmaceutical firm were up over 1% in Thursday's late morning trade.
Earnings per share came in at 0.1278 yuan, compared with 0.1067 yuan a year earlier.
Operating revenue fell 4.6% to 1.33 billion yuan from 1.39 billion yuan in the prior-year period.